ArticleCureus2026
Concomitant Aortic Valve Neocuspidization and Resection of a Cardiac Calcified Amorphous Tumor in a Hemodialysis Patient: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac calcified amorphous tumor (CAT) is an uncommon nonneoplastic intracardiac lesion associated with end-stage renal disease; mobile lesions carry an embolic risk and are generally resected. A 62-year-old man on maintenance hemodialysis was found to have a mobile verrucous mass 17 mm long on the anterior mitral leaflet and a separate immobile calcified lesion, 19 × 12 mm, at the base of the posterior mitral leaflet, together with moderate aortic regurgitation, left ventricular dilatation, a left ventricular ejection fraction of 41%, and pulmonary hypertension. Infective endocarditis was considered unlikely because blood cultures were negative and there was no inflammatory response; a noninfective thrombotic lesion was suspected, but four months of warfarin produced no regression of either lesion. Because open-heart surgery was required for the mobile mass, the aortic valve was addressed at the same operation. Each prosthetic option carried a disadvantage: a bioprosthesis could undergo accelerated structural deterioration in the same calcifying environment, and a mechanical valve would require lifelong anticoagulation, which in dialysis carries a bleeding hazard and may itself promote calcification. Aortic valve neocuspidization with glutaraldehyde-treated autologous pericardium was therefore chosen as an individualized alternative, with transaortic resection of the mobile mass; the immobile lesion was left unresected because of its proximity to the atrioventricular groove and left circumflex artery. Histology confirmed CAT. Aspirin was continued while warfarin was not resumed. Over three years of echocardiographic and 45 months of clinical follow-up, the reconstructed valve remained free of stenosis and paravalvular leak, ventricular function improved, the unresected lesion did not enlarge, and no thromboembolic or bleeding event occurred, although aortic regurgitation progressed to a mild-to-moderate degree.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.